These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37989630)

  • 1. Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall.
    Van Winden VI; Wong DD; Wood BA; Filion P; Harvey NT
    Pathology; 2024 Feb; 56(1):47-51. PubMed ID: 37989630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).
    Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
    Gleason BC; Nascimento AF
    Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
    Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
    Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
    Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
    J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
    Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
    Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
    Ruby KN; Li Z; Yan S
    J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
    Clarkson KS; Sturdgess IC; Molyneux AJ
    J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
    Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
    Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
    Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
    Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological features of metastatic melanoma in effusion cytology of serosal cavity].
    Xia Q; Chang XN; Huang B; Li XF; Luo DJ; Wang QJ; Jiang MT; Fan J; Zhou DW
    Zhonghua Bing Li Xue Za Zhi; 2024 Aug; 53(8):837-842. PubMed ID: 39103266
    [No Abstract]   [Full Text] [Related]  

  • 12. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
    Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
    Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
    Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
    Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of cutaneous granular cell tumor with unusual Melan-A expression in a child.
    Cheng NH; Smith D; Errickson C; Ashi S
    J Cutan Pathol; 2024 Jun; 51(6):434-438. PubMed ID: 38527927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.
    Orosz Z
    Histopathology; 1999 Jun; 34(6):517-25. PubMed ID: 10383696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience.
    Carvajal P; Zoroquiain P
    Pathol Res Pract; 2023 Oct; 250():154776. PubMed ID: 37696245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma.
    Hornick JL; Plaza JA; Mentzel T; Gru AA; Brenn T
    Am J Surg Pathol; 2023 Dec; 47(12):1390-1397. PubMed ID: 37727938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of PRAME immunohistochemistry in PEComa family of tumors and morphologic mimics with emphasis on the gynecologic tract.
    Smithgall MC; Liu-Jarin X; Chen X; Singh K; Quddus MR; Cimic A
    Hum Pathol; 2023 Aug; 138():12-17. PubMed ID: 37209921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
    Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
    Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.